The science of Immuno Oncology is rapidly evolving and increasing in its complexity. The Gradalis Scientific Advisory Board (SAB) was formed in October 2016, to provide guidance to the Gradalis leadership team on scientific and clinical matters related to Vigil Engineered Autologous Tumor Cell Immunotherapy (EATC) technology.

The Gradalis SAB is chaired by Sir. Marc Feldmann, AC FRS, a preeminent immunologist with expertise in autoimmune diseases and cancer immunology.  He is joined by Dr. Steven Burakoff, MD, Director, Tisch Cancer Research Center, Mount Sinai Hospital, New York, and a world renouned expert in Cellular Immunology and T-cell activation.

Dr. Brian Daniels, ex-Senior Vice President, Global Development and Medical Affairs, Bristol-Myers Squibb Company, is the third member of the Scientific Advisory Board.  Dr. Daniels, an immunologist by training, brings years of drug development expertise to the Scientific Advisory Board.

Marc Feldmann   Steve Burakoff   Brian Daniels
Sir Marc Feldmann AC, FRS   Steve Burakoff, MD   Brian Daniels, MD